EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer
Authors
Keywords
-
Journal
Molecular Oncology
Volume 10, Issue 4, Pages 601-609
Publisher
Wiley
Online
2015-11-24
DOI
10.1016/j.molonc.2015.11.007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
- (2015) Frederick H. Wilson et al. CANCER CELL
- Evaluation of EML4-ALK Fusion Proteins in Non–Small Cell Lung Cancer Using Small Molecule Inhibitors
- (2015) Yongjun Li et al. NEOPLASIA
- Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
- (2014) Arjan Gower et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Molecular mechanisms of epithelial–mesenchymal transition
- (2014) Samy Lamouille et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation
- (2013) Hyeong Ryul Kim et al. Molecular Oncology
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2013) Jim Sang et al. Cancer Discovery
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Cancer stem cells and epithelial–mesenchymal transition: Concepts and molecular links
- (2012) Christina Scheel et al. SEMINARS IN CANCER BIOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
- (2011) E Normant et al. ONCOGENE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
- (2010) K Vuoriluoto et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now